An independent international safety monitoring board has given the ENIGMA-TRS 1 trial the go-ahead to continue as planned.
The patient death occurred outside the U.S. and was deemed unrelated to Newron Pharmaceuticals’ investigational schizophrenia ...
The FDA has halted U.S. enrollment for Newron Pharmaceuticals’ phase 3 schizophrenia trial, following the death of a patient ...
The Food and Drug Administration (FDA) has placed a hold on the enrollment of new patients in the phase 3 ENIGMA-TRS 2 study evaluating evenamide in treatment-resistant schizophre ...
New long-term data from Study 304 confirms lumateperone 42mg significantly delays time to relapse in clinically stable patients with schizophrenia.
Mr. T was in his late 50s and being treated for schizophrenia, noninsulin-dependent diabetes, and hypertension. He had lived in the same assisted-living facility for the past four years and had ...
Scientists from NIMHANS and IIT Bhubaneswar have developed a novel approach to study schizophrenia using Chaos Theory to analyze brain signals. This research introduces the Chaotic Dynamics Marker ...
More than 92% of schizophrenia patients taking TEV-'749 in the SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication 1 New data from UZEDY ® ...
Schizophrenia was associated with cardiac electrical instability, suggesting arrhythmic vulnerability was an intrinsic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results